Showing results (1081-1090 of 6,317) with videos related to

Sort By:
Pageof 632
Diabetes, Obesity & Metabolism|August 17, 2016
Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trialJuan P Frías, Samer Nakhle, James A Ruggles, et al.
Diabetes, Obesity & Metabolism|October 23, 2019
Oral semaglutide for type 2 diabetes: A systematic review and meta-analysisIoannis Avgerinos, Theodoros Michailidis, Aris Liakos, et al.
Diabetes, Obesity & Metabolism|April 22, 2020
COVID-19 infection may cause ketosis and ketoacidosisJuyi Li, Xiufang Wang, Jian Chen, et al.
Diabetes, Obesity & Metabolism|April 22, 2020
Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB)Toru Kitazawa, Hiroaki Seino, Hiroshi Ohashi, et al.
Diabetes, Obesity & Metabolism|April 22, 2020
A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutideIn Bok An, Mi Sun Byun, Sang In Yang, et al.
Diabetes, Obesity & Metabolism|September 2, 2021
Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trialsEiichi Araki, Yasuo Terauchi, Hirotaka Watada, et al.
Diabetes, Obesity & Metabolism|September 24, 2025
Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetesSarah Béland-Bonenfant, Damien Denimal, Jean-Paul Pais-de-Barros, et al.
Diabetes, Obesity & Metabolism|September 12, 2025
Comparative efficacy and safety of Glucagon-like pepetide-1 receptor agonists with metformin in Asian versus non-Asian patients with type 2 diabetes: A systematic review and meta-analysisWenxuan Li, Linyan Huang, Ruixue Wang, et al.
Diabetes, Obesity & Metabolism|September 15, 2025
Blood glucose trajectories in diabetes patients receiving CAPDCA model of personalised patient education: A cluster randomised controlled trialJie Li, YuJiang Liu, Wei Xing, et al.
Diabetes, Obesity & Metabolism|September 16, 2025
Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative studyXin Li, Yi Zhang, Yan Bi, et al.
Pageof 632